+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dyskinesia"

Tavapadon Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Tavapadon Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
From
From
Dyskinesia - Pipeline Insight, 2024 - Product Thumbnail Image

Dyskinesia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2024 - Product Thumbnail Image

Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Parkinson's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 230 Pages
  • Global
From
Primary Ciliary Dyskinesia (PCD) - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Ciliary Dyskinesia (PCD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Tardive dyskinesia - Pipeline Insight, 2024 - Product Thumbnail Image

Tardive dyskinesia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Serotonin 1B receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin 1B receptor agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Global Tourette Syndrome Treatment Market - Product Thumbnail Image

Global Tourette Syndrome Treatment Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
Global Tardive Dyskinesia Treatment Market 2024-2028 - Product Thumbnail Image

Global Tardive Dyskinesia Treatment Market 2024-2028

  • Report
  • November 2023
  • 147 Pages
  • Global
From
From
From
From
Loading Indicator

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression. The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms. Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more